1 Gupta S, Nair NS, Hawaldar RW, et al. Addition of platinum to sequential taxaneanthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. Presented at: 2022 San Antonio Breast Cancer 
2 SCyitmropno sMiuL,m ;B eDrercy eDmAb, eCr ir6r-i1n0ci, o2n0e2 2C;,  Seta nal .A Rntaonndioo, mTizX.e dA tbrsi tarl aocft  dGoSse5--d0e1.nse versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003;21:1431-1439.   
3 Jones S, Holmes F, O’Shaughnessey J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and  cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. J Clin Oncol 2009;27:1177-1183; Nitz U, Gluz O, Clemens M, et al. West German Study PlanB Trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019;37:799-808.   
4 Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med, 2020;382:810-821.   
5 Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017;376:2147-2159.   
6 Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021;384:2394-2405.   
7 von Minckwitz G1, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.   
8 Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-3110. 
9 Martin, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:22.   
10 Sharma P, Kimler BF, O'Dea A, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res 2021;27:975-982. 
11 Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol 2020;6:1390-1396.   
12 von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15:747-756.   
13 Sharma P, Lopez-Tarruella S, Garcia-Saenz J, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts. Clin Cancer Res 2017;23:649-657.   
14 Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer 2022;150:654-662.   
15 Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6  months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast  cancer patients with tamoxifen-nonresponsive tumors: results from the National  Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-1496.
16 Goldhirsch A, Colleoni M, Coates AS, et al: Adding adjuvant CMF chemotherapy to  either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer  Study Group (IBCSG). Ann Oncol 1998;9:489-493.
17 Jakesz R, Hausmaninger H, Kubista E, et al. Austrian Breast and Colorectal Cancer Study  Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,  methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade  in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and  Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-4627.  
18 Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in adjuvant treatment of breast  cancer. N Engl J Med 2008;258:1663-1671.  
19 Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower  dosage and higher frequency vs observation on disease-free survival among patients with earlystage triple-negative breast cancer who had received standard treatment: The SYSUCC-001  randomized clinical trial. JAMA 2021;325:50-58.  
20 Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant  pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase  2 clinical trial. JAMA Oncol 2024;10:227-235.  
21 Tolaney S, Barry W, Dang C, et al. Adjuvant paclitaxel and trastuzumab for node-negative  HER2-positive breast cancer. N Engl J Med 2015;372:134-141.  
22 Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer.  N Engl J Med 2011;365:1273-1283.  
23 Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with  standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens  in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study  (TRYPHAENA). Ann Oncol 2013;24:2278-2284.  
24 Romond EH, Perez EZ, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable  HER2 positive breast cancer. N Engl J Med 2005;353:1673-1684.  
25 Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and  cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu over-expressed/  amplified breast cancer. J Clin Oncol 2008;26:1216-1222.  
26 Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracyclineand taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive  localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac  safety study. Ann Oncol 2018;29:646-653.  
27 Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab  in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2  study. Lancet Oncol 2013;14:1121-1128.  
28 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or  without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.  
29 van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy  with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive  breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol  2018;19:1630-1640.  
30 Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and  trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast  cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol  2012;13:25-32.  
31 Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in  patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind,  placebo-controlled, phase 3 trial. Lancet Oncol 2016;17:367-377.  
32 Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast  cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and  predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab  ± weekly paclitaxel. Ann Oncol 2017;28:2768-2772.  
33 Tolaney SM, Tayob N, Dang C, et al. Adjuvant trastuzumab emtansine versus paclitaxel in  combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized  clinical trial. J Clin Oncol 2021;39:2375-2385.